[ 1] NIH.2018USRDSAnnualdatareport.2018;Availablefrom:https://www.usrds.org/2018/view/v2_05.aspx
[ 2] Rubinger D , Backenroth R , Sapoznikov D . Sympathetic nervous system function and dysfunction in chronic hemodialysis patients.[J]. Seminars in Dialysis, 2013, 26(3):333-343.
[3] Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial[J]. The Lancet, 2017, 390(10108):2160-2170.
[4] Pietil?-Effati PM, Salmela A K , Niemi R T , et al. Renal sympathetic denervation in treating drug-resistant hypertension in a patient on hemodialysis[J]. Journal of Hypertension, 2016, 34(2):368.
[5] Pietil?-Effati P?ivi M,Salmela Anna K,Koistinen M Juhani,Intravascular Renal Denervation in Renal Dialysis Patients with Uncontrolled Hypertension: A Case Series of Four Patients.[J] .Am J Case Rep, 2018, 19: 985-991.
[6] Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease
[7] Hoye Neil A,Wilson Luke C,Wilkins Gerard T et al. Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection-A Proof-of-Concept Study.[J] .Kidney Int Rep, 2017, 2: 856-865.
[8]Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center fea- sibility study. J Am Coll Cardiol. 2010;56:1254–1258. doi: 10.1016/j. jacc.2010.03.089.
[9]Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pres- sure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal trial. J Am Coll Cardiol. 2011;58:765–773. doi: 10.1016/j.jacc.2011.06.008.
[10]Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, Pertile T, Kieval R, Cody R. An implantable carotid sinus stimulator for drug- resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:1213– 1218. doi: 10.1016/j.jvs.2006.08.024.
[11]Leeuw P W D , Bisognano J D , Bakris G L , et al. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up[J]. Hypertension, 2017, 69(5):HYPERTENSIONAHA.117.09086.
[12]Joachim, Koziolek, Michael J , et al. Baroreflex activation therapy in patients with end-stage renal failure:, proof of concept[J]. Journal of Hypertension, 2015, 33(11):2344-9.
[13] Kobayashi Norihiro,Muramatsu Toshiya,Tsukahara Reiko et al. Influence of hemodialysis duration on mid-term clinical outcomes in hemodialysis patients with coronary artery disease after drug-eluting stent implantation.[J] .Heart Vessels, 2016, 31: 330-40.
[14] Khera Sahil,Villablanca Pedro A,Kolte Dhaval et al. Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis: A Systematic Review and Meta-Analysis.[J] .Cardiol Rev, 2018, 26: 277-286.
[15] Otsuka Masaya,Shiode Nobuo,Masaoka Yoshiko et al. Comparison of everolimus- and paclitaxel-eluting stents in dialysis patients.[J] .Cardiovasc Revasc Med, 2015, 16: 208-12.
[16] Kumada Yoshitaka,Ishii Hideki,Aoyama Toru et al. Long-term clinical outcome after surgical or percutaneous coronary revascularization in hemodialysis patients.[J] .Circ. J., 2014, 78: 986-92.
[17] Bleyer A J , Hartman J , Brannon P C , et al. Charcteristics of sudden death in hemodialysis patients[J]. Kidney International, 2006, 69(12):2268-2273.
[18] Herzog Charles A,Li Shuling,Weinhandl Eric D et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators.[J] .Kidney Int., 2005, 68: 818-25.
[19] Charytan David M,Patrick Amanda R,Liu Jun et al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.[J] .Am. J. Kidney Dis., 2011, 58: 409-17.
[20]Alpert Martin A,Sudden cardiac arrest and sudden cardiac death on dialysis: Epidemiology, evaluation, treatment, and prevention.[J] .Hemodial Int, 2011, null: S22-9.
[21] Pun Patrick H,Hellkamp Anne S,Sanders Gillian D et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.[J] .Nephrol. Dial. Transplant., 2015, 30: 829-35.
[22] Nakhoul Georges N,Schold Jesse D,Arrigain Susana et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.[J] .Clin J Am Soc Nephrol, 2015, 10: 1119-27.
[23] Sakhuja Rahul,Keebler Mary,Lai Tai-Shuan et al. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator.[J] .Am. J. Cardiol., 2009, 103: 735-41.
[24] El-Chami Mikhael F,Levy Mathew,Kelli Heval M et al. Outcome of Subcutaneous Implantable Cardioverter Defibrillator Implantation in Patients with End-Stage Renal Disease on Dialysis.[J] .J. Cardiovasc. Electrophysiol., 2015, 26: 900-904.
[25] Koman Eduard,Gupta Ashwani,Subzposh Faiz et al. Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis.[J] .J Interv Card Electrophysiol, 2016, 45: 219-23.
[26] Potpara T S , Ferro C J , Lip G Y H . Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction[J]. Nature Reviews Nephrology, 2018, 14(5).
[27] Ronco Federico,Mazzone Patrizio,Hosseinian Leila et al. Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease.[J] .Cardiorenal Med, 2017, 7: 207-217.
[28] Holmes DR, et al: Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of ?stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009;374:534–542. ?
[29] Reddy VY, Doshi SK, Holmes DR, et al: Percutaneous left atrial appendage closure for stroke prophylaxis in ?patients with atrial fibrillation: 2.3 year follow-up of the PROTECT-AF Trial. Circulation 2013;127:720–729. ?
[30] Genovesi S , Slaviero G , Porcu L , et al. Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population[J]. International Journal of Cardiology, 2018, 262:38-42.
[31] Kefer J , Tzikas A , Freixa X , et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation[J]. International Journal of Cardiology, 2016, 207:335-340.
